Skip to main content
SpringerLink
Log in

Tumoren in der Neurologie

ZNS-Manifestationen bei Lymphomen

  • Zertifizierte Fortbildung Neurologie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Kadan-Lottick NS et al. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002; 95: 193-202

  2. Hoang-Xuan K et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015; 16: e322-32

  3. Ferreri AJ et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20

  4. Omuro A et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015; 2: e251-9

  5. Thiel E et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-47

  6. Ferreri AJ et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3: e217-27

  7. Ferreri AJM et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 2017; 4: e510-e23

  8. Houillier C et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Randomized Phase II PRECIS Study. J Clin Oncol 2019; 37: 823-33

  9. Kickingereder P et al. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility- weighted MR imaging. Radiology 2014; 272: 843-50

  10. Louis DN et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-20

  11. Ostrom QT et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 2019; 21: v1-v100

  12. Kluin PM DM, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH CE, Harris NL, (Hrsg.). World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. IARC Press, 2008;240-1

  13. Villano JL et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011; 105: 1414-8

  14. Bessell EM et al. Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma. J Neurooncol 2011; 104: 191-3

  15. O'Neill BP et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol 2013; 88: 997-1000

  16. Weller M et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315-e29

  17. Weller Met al. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012; 14: 1481-4

  18. Schultz C et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556-64

  19. Glass J et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188-95

  20. Hiraga Set al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999; 91: 221-30

  21. Bergner N, Monsef I, Illerhaus G, Engert A, Skoetz N. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev 2012; 11: CD009355

  22. Rubenstein JL et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31:3061-8

  23. Neuwelt EA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90

  24. Sierra Del Rio Met al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol 2012; 106: 143-6

  25. Pels H et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-95

  26. Bromberg JEC et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2019; 20:216-28

  27. Schorb E et al. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer 2019; 19: 287

  28. Seidel S et al. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series. Ther Adv Neurol Disord 2020; 13: 1756286420951087

  29. Fritsch K et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 2017; 31: 846-52

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Tübingen, Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie, Zentrum für Neuroonkologie, Comprehensive Cancer Center Tübingen-Stuttgart, Otfried-Müller Str. 10, 72076, Tübingen, Germany

    Ghazaleh Tabatabai

  2. Universitätsklinikum Tübingen, Medizinische Klinik, Innere Medizin IIZentrum für NeuroonkologieComprehensive Cancer Center Tübingen-Stuttgart, Otfried-Müller Str. 10, 72076, Tübingen, Germany

    Robert Möhle

Authors
  1. Ghazaleh Tabatabai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Möhle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghazaleh Tabatabai.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. G.T. war in Advisory boards von AbbVie, Bayer und BMS tätig, erhielt Beratungsgebühren von AbbVie, Bayer, erhielt Rednerhonorare von Medac und Novocure; erhielt Reisestipendien von Novocure, Medac und BMS, erhielt Forschungsstipendien von Roche Diagnostics und Medac, die alle nicht mit dieser Arbeit zusammenhängen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tabatabai, G., Möhle, R. ZNS-Manifestationen bei Lymphomen. InFo Neurologie 23, 42–49 (2021). https://doi.org/10.1007/s15005-021-1837-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-021-1837-4

Search

Navigation